Metabolic Disorders in Polycystic Ovarian Syndrome
Metabolic Disorders in Polycystic Ovarian Syndrome
The purpose of this study is to elucidate the significance of adipocytokine in women with
 PCOS among adiposity, hyperandrogenism and insulin resistance.
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive
 age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation,
 menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as
 hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal
 and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese,
 and the presence of obesity affects the clinical manifestations of PCOS. The underlying
 pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the
 magnitude of which is greater in obese than in non-obese women with PCOS.
Inclusion Criteria:

 -  1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2.
 Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After
 menarche, before menopause.

 Exclusion Criteria:

 -  1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute
 illness found in the past 3 months. 4.Systemic disease including autoimmune disease,
 malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or
 immunosuppressive agents.